Background: Nongestational ovarian choriocarcinoma (NGOC) is a rare but aggressive neoplasm with limited sensitivity to chemotherapy and a very poor prognosis. Few cases of NGOC have been reported, and there is limited information regarding its clinical features, treatment protocols, or prognosis.
Case Summary: A postmenopausal woman in her 5 decade of life visited our clinic because of abnormal vaginal bleeding and an abdominal mass. Although she had been menopausal for more than eight years and her last abortion occurred nine years ago, she had an increased level of serum β-human chorionic gonadotropin (β-hCG). Thus, an ovarian neoplasm of trophoblastic origin was suspected, and exploratory laparotomy was performed. Based on the patient's clinical history and the histopathological examination and immunohistochemistry results obtained postoperatively, we concluded that she most likely had primary NGOC. Cytoreductive surgery was performed in combination with adjuvant chemotherapy comprising bleomycin, etoposide, and cisplatin. Serum β-hCG levels decreased to normal after two cycles, and there was no evidence of recurrence after four cycles of chemotherapy.
Conclusion: Even in postmenopausal women, ovarian choriocarcinoma should be considered in the initial differential diagnosis for an adnexal mass.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10294203 | PMC |
http://dx.doi.org/10.12998/wjcc.v11.i15.3592 | DOI Listing |
Cureus
November 2024
Oncology, University Hospital Waterford, Waterford, IRL.
Non-gestational choriocarcinoma is an extremely rare and highly aggressive malignant tumor that arises independent of gestational events, making less than 0.6% of all ovarian germ cell tumors. Unlike the more common gestational choriocarcinoma, which is associated with pregnancy, non-gestational choriocarcinoma originates from germ cells within the ovary.
View Article and Find Full Text PDFInt J Gynecol Pathol
October 2024
Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
Eur J Case Rep Intern Med
September 2024
Department of Hematology/Oncology, Texas Tech University Health Science Center, Lubbock, USA.
Unlabelled: Choriocarcinomas are uncommon tumors, with non-gestational types occurring in both males and females. Primary choriocarcinoma of the colon is extremely rare. It presents significant diagnostic and therapeutic challenges due to its aggressive nature and poor prognosis, with no cure available, and a mean survival of 8 months.
View Article and Find Full Text PDFCureus
August 2024
Obstetrics and Gynecology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU.
Non-gestational choriocarcinoma of the ovary is extremely rare and presents diagnostic and therapeutic challenges. Early recognition, appropriate surgical intervention, and adjuvant chemotherapy are essential for successful management. This case underscores the importance of considering choriocarcinoma in the differential diagnosis of ovarian tumors, especially in perimenopausal women with vascular mass.
View Article and Find Full Text PDFReprod Sci
October 2024
Reproductive Medicine Center, The First Hospital of Lanzhou University, No. 1 Dong Gang Xi Road, Chengguan District, Lanzhou, 730000, Gansu, China.
To retrospectively analyze the fertility outcomes and prognosis of gestational trophoblastic disease (GTD) patients, providing a basis for targeted fertility guidance and counseling. 82 GTD patients of childbearing age who received treatment at the Obstetrics and Gynecology Department of Lanzhou University First Hospital from January 2016 to January 2023 were stratified into re-pregnancy (n = 20) and non-re-pregnancy (n = 33) cohorts based on their pregnancy outcomes. The impacts of various factors on pregnancy outcomes were subsequently evaluated, encompassing the rates of subsequent pregnancies, live births, miscarriages, ectopic pregnancies, and ongoing pregnancies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!